It remains to be seen though if Tukysa could also be combined with Enhertu to good effect ... this setting. Seagen said no new safety signals had emerged for the combination. Pfizer reached ...

The integration of Seagen's portfolio and expertise is ... success in the weight management sector could have synergistic effects with Pfizer's other therapeutic areas, such as cardiovascular ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

Pfizer (NYSE: PFE) has been around for 175 years ... reinforce its oncology business -- the purchase of cancer specialist Seagen. Pfizer's biggest launch period ever -- with 19 product releases ...

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation ... to increase efficacy with fewer side effects. — Bloomberg ...

PFE’s New Drugs & Seagen Acquisition to Drive Growth Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven by its key in-line products like ...

New cancer drugs from the $43 billion acquisition of Seagen also aided sales. Pfizer reaffirmed its 2025 guidance of revenue between $61 billion and $64 billion, and of adjusted per-share earnings ...

Higher sales of Pfizer’s key non-COVID products like Vyndaqel, Padcev and Eliquis and newly acquired products from Seagen, coupled with higher Paxlovid sales, drove the top line in the quarter.

Pfizer’s acquisition of Seagen in December 2023 added antibody ... under the Inflation Reduction Act (IRA), which takes effect in 2025. Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi ...